After unveiling Phase II data on 27 February for a GLP-1/GIP agonist showing absolute weight reduction up to 14.7% after 13 weeks, Viking Therapeutics, Inc. now may be a contender in the burgeoning weight loss/obesity space. Despite the glowing reception of what the firm called “preliminary efficacy” findings, Viking expects that the next step will be a Phase IIb study that works out dosing issues and looks at longer term effects.
Viking Emerges As Obesity Contender With Strong Phase II Readout
An analyst is calling data from Viking’s Phase II study of GLP-1/GIP agonist VK2735 best-in-class, even compared with approved therapies, with 13-week weight reductions as high as 14.7%.
More from Clinical Trials
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
More from R&D
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.